A method using high-performance liquid chromatography for the simultaneous determination of seven principal constituents including xanthoxylol, kakuol, methyleugenol,l-sesamin, safrole, sarisan, and l-asarinin in Asar...A method using high-performance liquid chromatography for the simultaneous determination of seven principal constituents including xanthoxylol, kakuol, methyleugenol,l-sesamin, safrole, sarisan, and l-asarinin in Asari Radix et Rhizoma （Xixin in Chinese） was developed. Fifty five samples of Asari Radix et Rhizoma from different sources （35 samples from Asarum heterotropoides var. mandshuricum, 3 samples from Asarum sieboldii var. seoulense, and 17 samples from Asarum sieboldii） were analyzed with this method. Chromatographic separation was achieved on an Agilent Zorbax SB-C18 column （4.6 mm×25 cm, 5 μm） using a gradient elution with mobile phase of aqueous （A） and acetonitrile （B）. The assay was carried out at 20 ℃ and with detection at 287 nm. All calibration curves showed good linearity （r2〉0.999） within the tested ranges. The average recoveries were in the range of 96.0%-103.1% with relative standard deviation （RSD） less than 2.54%. The developed method was accurate with high sensitivity and good reproducibility. The content of volatile methyleugenol in LiaoXixin （the root and rhizome ofA. heterotropoides var. mandshuricum and A. sieboldii var. seoulense） was （6.17±5.13） rag/g, which was higher than （0.58±0.40） mg/g in HuaXixin （the root and rhizome ofA. sieboldii）. The toxic safrole in LiaoXixin was （2.66±2.16） mg/g, which was lower than （6.44±3.89） mg/g in HuaXixin. This is the first report on the simultaneous and quantitative determination of anthoxylol and sarisan in Asari Radix et Rhizoma.展开更多
Objective:Although some studies have linked Asari Radix et Rhizoma(Asari Radix)administration to hepatocellular carcinoma(HCC),few studies have examined the association between the development of HCC and use of Asari ...Objective:Although some studies have linked Asari Radix et Rhizoma(Asari Radix)administration to hepatocellular carcinoma(HCC),few studies have examined the association between the development of HCC and use of Asari Radix among patients in China's Mainland.This study aimed to evaluate the realworld association between Asari Radix and HCC in patients to strengthen the understanding of Asari Radix safety.Methods:A retrospective cohort study among hepatitis B virus(HBV)-monoinfected patients and nonHBV-monoinfected patients were performed.Patients over 18 years of age were eligible for inclusion.Prescription records of inpatients and outpatients were inquired to distinguish Asari Radix users and nonusers.The risk of developing HCC among Asari Radix users and nonusers in the HBV cohort and the non-HBV cohort was analyzed.Results:There were 49500 HBV and 133148 non-HBV patients involved in the two cohorts.Among HBV patients(2901 users;46599 nonusers),the prevalence of HCC in Asari Radix users was lower than that in nonusers(145.70 vs.265.43 per 105).Among non-HBV patients(5042 users;128106 nonusers),the prevalence of HCC in Asari Radix users was lower than that in nonusers(81.62 vs.134.11 per 105).None of the hazard ratios(HRs)of Asari Radix exposure ranging from 1 g to 200 g in the two cohorts showed correlation between Asari Radix exposure and hepatocarcinogenesis.Conclusion:An obvious irrelevancy was found between the consumption of Asari Radix and HCC development both in patients with and in those without HBV infection.Use of Asari Radix under 200 g appears safe in terms of HCC risk in the Chinese population;further prospective studies are needed to confirm our results.展开更多
基金supported by grants from the National Key Research and Development Program on the Modernization of Traditional Chinese Medicine (2022YFC3502104 to R.L.and R.S.)the recipient of a Research Career Scientist Award from the Department of Veterans Affairs (IK6BX004477)。
基金National Basic Research Program of China （Grant No. 2006CB504707）, National Science and Technology Major Projects for ＂Major New Drugs Innovation and Development＂ （Grant No. 2013ZX09508104） and National Natural Science Foundation of China （Grant No. 81274073）.
文摘A method using high-performance liquid chromatography for the simultaneous determination of seven principal constituents including xanthoxylol, kakuol, methyleugenol,l-sesamin, safrole, sarisan, and l-asarinin in Asari Radix et Rhizoma （Xixin in Chinese） was developed. Fifty five samples of Asari Radix et Rhizoma from different sources （35 samples from Asarum heterotropoides var. mandshuricum, 3 samples from Asarum sieboldii var. seoulense, and 17 samples from Asarum sieboldii） were analyzed with this method. Chromatographic separation was achieved on an Agilent Zorbax SB-C18 column （4.6 mm×25 cm, 5 μm） using a gradient elution with mobile phase of aqueous （A） and acetonitrile （B）. The assay was carried out at 20 ℃ and with detection at 287 nm. All calibration curves showed good linearity （r2〉0.999） within the tested ranges. The average recoveries were in the range of 96.0%-103.1% with relative standard deviation （RSD） less than 2.54%. The developed method was accurate with high sensitivity and good reproducibility. The content of volatile methyleugenol in LiaoXixin （the root and rhizome ofA. heterotropoides var. mandshuricum and A. sieboldii var. seoulense） was （6.17±5.13） rag/g, which was higher than （0.58±0.40） mg/g in HuaXixin （the root and rhizome ofA. sieboldii）. The toxic safrole in LiaoXixin was （2.66±2.16） mg/g, which was lower than （6.44±3.89） mg/g in HuaXixin. This is the first report on the simultaneous and quantitative determination of anthoxylol and sarisan in Asari Radix et Rhizoma.
基金supported by grants from "the National Science and Technoloyg Major Project" Key New Drug Creation and Manufacturing Program (2018ZX09101002-001-002)Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No:ZYYCXTD-C-202005)
文摘Objective:Although some studies have linked Asari Radix et Rhizoma(Asari Radix)administration to hepatocellular carcinoma(HCC),few studies have examined the association between the development of HCC and use of Asari Radix among patients in China's Mainland.This study aimed to evaluate the realworld association between Asari Radix and HCC in patients to strengthen the understanding of Asari Radix safety.Methods:A retrospective cohort study among hepatitis B virus(HBV)-monoinfected patients and nonHBV-monoinfected patients were performed.Patients over 18 years of age were eligible for inclusion.Prescription records of inpatients and outpatients were inquired to distinguish Asari Radix users and nonusers.The risk of developing HCC among Asari Radix users and nonusers in the HBV cohort and the non-HBV cohort was analyzed.Results:There were 49500 HBV and 133148 non-HBV patients involved in the two cohorts.Among HBV patients(2901 users;46599 nonusers),the prevalence of HCC in Asari Radix users was lower than that in nonusers(145.70 vs.265.43 per 105).Among non-HBV patients(5042 users;128106 nonusers),the prevalence of HCC in Asari Radix users was lower than that in nonusers(81.62 vs.134.11 per 105).None of the hazard ratios(HRs)of Asari Radix exposure ranging from 1 g to 200 g in the two cohorts showed correlation between Asari Radix exposure and hepatocarcinogenesis.Conclusion:An obvious irrelevancy was found between the consumption of Asari Radix and HCC development both in patients with and in those without HBV infection.Use of Asari Radix under 200 g appears safe in terms of HCC risk in the Chinese population;further prospective studies are needed to confirm our results.
